For the quarter ending 2025-09-30, ALGS made $741,000 in revenue. -$31,502,000 in net income. Net profit margin of -4251.28%.
| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|
| Revenue from customers | 741,000 | 965,000 | - | 105,000 |
| Research and development | 23,937,000 | 13,976,000 | 14,502,000 | 17,831,666.667 |
| General and administrative | 5,165,000 | 5,556,000 | 5,052,000 | 6,068,000 |
| Total operating expenses | 29,102,000 | 19,532,000 | 19,554,000 | 23,899,666.667 |
| Revenue from customers | - | - | 311,000 | 787,000 |
| Loss from operations | -28,361,000 | -18,567,000 | -19,243,000 | -23,007,666.667 |
| Interest and other income, net | 1,085,000 | 1,207,000 | 880,000 | 1,147,666.667 |
| Change in fair value of 2023 common warrants | 4,205,000 | -1,682,000 | -61,494,000 | 7,688,666.667 |
| Loss before income tax | -31,481,000 | -15,678,000 | 43,131,000 | -37,237,333.333 |
| Income tax provision | 56,000 | 185,000 | 43,000 | 80,000 |
| Net loss | -31,537,000 | -15,863,000 | 43,088,000 | -37,317,333.333 |
| Unrealized gain on available-for-sale securities | 35,000 | -27,000 | -4,000 | -24,666.667 |
| Unrealized (loss) gain on pension plans | - | - | - | 17,166.667 |
| Other comprehensive gain | 35,000 | -27,000 | -4,000 | -59,000 |
| Comprehensive loss | -31,502,000 | -15,890,000 | 43,084,000 | -37,376,333.333 |
| Earnings per share, basic, total | -3.04 | -1.53 | 5.12 | -5.957 |
| Earnings per share, diluted, total | -3.04 | -1.53 | -2.11 | -5.957 |
| Weighted average number of shares outstanding, basic, total | 10,369,535 | 10,351,120 | 8,408,481 | -2,559.667 |
| Weighted average shares of common stock, diluted | 10,369,535 | 10,351,120 | 8,709,693 | -2,559.667 |
Aligos Therapeutics, Inc. (ALGS)
Aligos Therapeutics, Inc. (ALGS)